2017-03-17,Caladrius Biosciences Announces 2016 Fourth Quarter And Full Year Financial Results
2017-03-16,Hitachi Chemical Signs Agreement To Purchase From Caladrius Biosciences The Remaining 80.1% Interest In PCT For $75 Million
2017-03-13,Caladrius Biosciences To Host 2016 Fourth Quarter And Full Year Financial Results Conference Call On March 17, 2017 At 8:30 Am Eastern Time
2017-03-02,Caladrius Biosciences To Present At Upcoming March Conferences
2017-02-23,Caladrius Biosciences Awarded $12.2 Million Grant From CIRM In Support Of Phase 2 Clinical Trial Of CLBS03 To Treat Type 1 Diabetes
2017-02-01,Caladrius Biosciences To Present At Upcoming February Conferences
2017-01-25,Caladrius Biosciences Announces Addition Of Three Clinical Sites, Including University Of California, San Francisco, For The Ongoing Phase 2 Study Of CLBS03 In T1D
2017-01-06,Caladrius Biosciences Updates Status Of Receipt Of Funds For A Portion Of Previously Announced Private Placement
2017-01-03,Caladrius Biosciences To Present At Upcoming January Conferences
2016-12-05,Caladrius Biosciences To Present At Upcoming December Conferences
2016-11-22,Caladrius Biosciences Subsidiary, PCT, Earns FACT Re-Accreditation For Its Cell Therapy Development And Manufacturing Facilities
2016-11-07,Caladrius Biosciences Reports 2016 Third Quarter Financial Results
2016-11-02,Caladrius Biosciences To Host 2016 Third Quarter Financial Results Conference Call On November 7 At 5:00 Pm Eastern Time
2016-10-31,Caladrius Biosciences Begins Enrollment Of Second Cohort Of Phase 2 Trial Of CLBS03 As A Treatment For Type 1 Diabetes Following Favorable Safety Data From First Cohort
2016-10-27,Caladrius Biosciences To Present At Upcoming November Conferences
2016-10-12,Caladrius Biosciences Appoints Gregory R. Brown, MD, To Its Board Of Directors
2016-10-04,Caladrius Biosciences To Present At Upcoming October Conferences
2016-09-19,Caladrius Subsidiary, PCT, Announces Five-Year Strategic Manufacturing Services Agreement With Adaptimmune
2016-09-15,Caladrius Biosciences, Inc. Enters Into Agreements To Raise $25 Million In Common Equity Priced At Market Without Warrants
2016-09-08,Caladrius Biosciences To Present At Upcoming September Conferences
2016-09-06,Caladrius Biosciences Completes Enrollment Of First Patient Cohort In Phase 2 Trial Of CLBS03 To Treat Type 1 Diabetes
2016-08-09,Caladrius Biosciences Reports 2016 Second Quarter Financial Results
2016-08-02,Caladrius Biosciences To Host 2016 Second Quarter Financial Results Conference Call On August 9 At 5:00 Pm Eastern Time
2016-07-28,Caladrius Biosciences Receives FDA Fast Track Designation For CLBS03 To Treat Recent Onset Type 1 Diabetes
2016-07-27,Caladrius Biosciences Announces 1-for-10 Reverse Split
2016-07-07,Caladrius Biosciences To Present At Upcoming July Conferences
2016-06-27,Caladrius Biosciences SVP And President Of PCT, Robert Preti, PhD, Named Chairman Of The Alliance For Regenerative Medicine
2016-06-21,Caladrius Subsidiary, PCT, To Manufacture Phase 3 Cell Therapy Product For Kiadis Pharma
2016-06-01,Caladrius Biosciences To Present At Upcoming June Conferences
2016-05-26,Caladrius Biosciences Licenses Cell Therapy Technology For Ovarian Cancer And Subleases Irvine Facility To AiVita Biomedical
2016-05-12,Caladrius Biosciences Receives Orphan Drug Designation For CLBS03 To Treat Type 1 Diabetes
2016-05-09,Caladrius Biosciences To Present At Multiple Upcoming May Conferences
2016-05-05,Caladrius Biosciences Reports 2016 First Quarter Financial Results
2016-05-05,5 Breakout Stocks Under $10 Set to Soar
2016-04-28,Caladrius Biosciences To Host 2016 First Quarter Financial Results Conference Call On May 5 At 5:00 Pm Eastern Time
2016-04-20,Caladrius Biosciences To Present At Multiple Upcoming April Conferences
2016-04-18,Caladrius Reaches Agreement With Japanese Regulators On Development Plan For CD34 Cell Therapy For Critical Limb Ischemia
2016-03-29,Caladrius Biosciences Announces First Subject Treated In CLBS03 Type 1 Diabetes Phase 2 Trial
2016-03-17,Caladrius Biosciences To Present At Multiple Upcoming March Conferences
2016-03-15,Caladrius Biosciences Announces 2015 Fourth Quarter And Full Year Financial Results
2016-03-14,Caladrius Biosciences Subsidiary PCT, LLC Enters Into Global Collaboration And License Agreement With Hitachi Chemical
2016-03-11,7 Stocks Under $10 Making Big Moves Higher
2016-03-08,Caladrius Biosciences To Host 2015 Fourth Quarter And Full Year Financial Results Conference Call On March 15 At 5:00 Pm Eastern Time
2016-02-17,Caladrius Biosciences Licenses Dermatology Cell Technology To AiVita Biomedical
2016-02-08,8 Stocks Under $10 Set to Soar
2016-01-28,Caladrius Biosciences Announces Presentations At Upcoming Investor Conferences In February
2016-01-22,8 Stocks Under $10 Making Big Moves Higher
2016-01-13,Caladrius Biosciences Announces Presentations At Multiple Upcoming Conferences In January
2016-01-11,Caladrius Biosciences Out-Licenses CD34 Technology To SPS Cardio, LLC For Chronic Heart Failure And Acute Myocardial Infarction
2016-01-06,Caladrius Tightens Strategic Focus And Provides 2016 Revenue Guidance
2015-12-23,UPDATE -- Caladrius Announces Changes To Its Board Of Directors
2015-12-23,Caladrius Announces Changes To Its Board Of Directors
2015-12-01,Caladrius Announces Publication Of Two-Year Results From Phase 1 Trial Of Type 1 Diabetes Product Candidate In Science Translational Medicine
2015-11-09,Caladrius Biosciences Presents Additional Data Supporting Lead Product Candidate For Metastatic Melanoma At SITC 2015
2015-11-05,Caladrius Biosciences Announces Third Quarter 2015 Financial Results And Provides Corporate Update
2015-11-02,Caladrius Biosciences To Present At Multiple Upcoming November Conferences
2015-10-29,Caladrius Biosciences To Host Third Quarter 2015 Financial Results Conference Call On November 5 At 5:00 Pm
2015-10-08,Caladrius Biosciences Announces Management And Board Changes
2015-10-01,Caladrius Biosciences To Present At Multiple Upcoming October Conferences
2015-09-30,Caladrius To Present Data Elucidating CLBS20 Mechanism Of Action
2015-09-24,Caladrius Biosciences Receives Award From The National Cancer Institute
2015-09-22,Caladrius Biosciences And Sanford Research Establish Strategic Collaboration With Goal Of Developing Major Advance In Treatment Of Type 1 Diabetes
2015-09-10,Caladrius To Present At Multiple Upcoming Conferences
2015-09-08,PCT, LLC, A Caladrius Company, To Manufacture EU-Compliant Cell Therapy Product For IRX Therapeutics, Inc. From Its New Jersey Facility
2015-09-01,4 Biotech Stocks Under $10 to Trade for Breakouts
2015-08-13,5 Stocks Under $10 Set to Soar
2015-08-06,Caladrius Biosciences, Inc. Announces Second Quarter 2015 Financial Results And Provides Corporate Update
2015-08-06,Correction: Caladrius Biosciences Announces Second Quarter 2015 Financial Results Conference Call
2015-07-30,Caladrius Biosciences Announces Second Quarter 2015 Financial Results Conference Call
2015-07-23,Caladrius Biosciences Announces NIH Grant To Fund Retinal Disease Research
2015-06-29,Caladrius Biosciences Establishes Cardiovascular Scientific Advisory Board To Support Ongoing Development Efforts Using CD34 Cells
2015-06-23,Caladrius Biosciences Announces First Patient Dosed In Phase 3 Immunotherapy Trial For Melanoma
2015-06-18,Caladrius Announces Research Collaboration With The University Of Southern California And California Institute Of Technology
2015-06-15,PCT, A Caladrius Company, Expands Relationship With ImmunoCellular Therapeutics To Provide Manufacturing For Their Phase 3 Trial
,
,
,
